This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Humanigen Dividend

Dividend criteria checks 0/6

Humanigen does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.2%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$0.45
Future Dividend Yield0%

Recent dividend updates

No updates

Recent updates

Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M

Aug 12

Humanigen plunges 57% as trial for COVID-19 therapy fails

Jul 13

Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Jul 06

Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

Oct 30
Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Jul 14
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.

Jun 14

Humanigen submits lenzilumab COVID-19 EUA application to FDA

May 28

Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy

May 05

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

May 05
Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Mar 31
We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Feb 26
Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Jan 29

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Jan 11

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Jan 04
We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Humanigen secures new U.S. patent for lenzilumab

Dec 28

Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme

Dec 17

Humanigen EPS misses by $0.16

Nov 11

Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19

Nov 06

Humanigen executes lenzilumab licensing deal in Asia for COVID-19

Nov 03

Humanigen Dosing Phase 3  Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 01

Dosing underway in lenzilumab late-stage study in COVID-19

Oct 30

Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19

Oct 29

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if HGEN.Q's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HGEN.Q's dividend payments have been increasing.


Dividend Yield vs Market

Humanigen Dividend Yield vs Market
How does HGEN.Q dividend yield compare to the market?
SegmentDividend Yield
Company (HGEN.Q)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.2%
Analyst forecast (HGEN.Q) (up to 3 years)0%

Notable Dividend: Unable to evaluate HGEN.Q's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HGEN.Q's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate HGEN.Q's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as HGEN.Q has not reported any payouts.


Discover strong dividend paying companies